QGEN · Qiagen N.V. · Financials

$50.86 +0.03 (+0.06%) Play latest call Q2 2026 earnings call transcript

Russell 1000 member Rebalance outlook locked

Market Cap

$10.49B

206.50M

Volume · Nov 5 4.17M Avg daily vol (3M) 3.67M

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Pull these statements through the financial statements API or MCP →

Revenue

$2.09B +5.7%

FY2025

Net Income

$424.88M +408.3%

FY2025

Gross Margin

62.18% +13.3pp

FY2025

Operating Margin

22.29% +17.4pp

FY2025

Diluted EPS

$1.94 +424.3%

FY2025

Operating Cash Flow

$654.33M -2.9%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	FY2026 (G)	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	-0.8%	+2.2%	+5.0%	—	$2.09B	$1.98B	$1.97B	$2.14B	$2.25B	$1.87B	$1.53B	$1.5B	$1.42B	$1.34B	$1.28B	$1.34B	$1.3B	$1.25B	$1.17B	$1.09B	$1.01B	$892.98M
Cost of Revenue	+1.5%	+4.4%	+5.7%	—	$790.5M	$1.01B	$731.62M	$756.96M	$800.84M	$637.63M	$521.16M	$500.89M	$494.98M	$493.34M	$454.33M	$479.57M	$486.49M	$430.43M	$419.94M	$371.87M	$342.75M	$293.29M
Gross Profit	-2.1%	+1.1%	+4.6%	—	$1.3B	$967.35M	$1.23B	$1.38B	$1.45B	$1.23B	$1.01B	$1B	$922.56M	$844.65M	$826.66M	$865.21M	$815.49M	$824.02M	$749.81M	$715.56M	$667.07M	$599.69M
Gross Margin	—	—	—	—	62.18%	48.9%	62.77%	64.65%	64.43%	65.91%	65.86%	66.65%	65.08%	63.13%	64.53%	64.34%	62.63%	65.69%	64.1%	65.8%	66.06%	67.16%
Research & Development	-0.4%	+4.7%	+2.5%	—	$187.52M	$193.49M	$198.51M	$189.86M	$189.96M	$149.07M	$157.45M	$161.85M	$154.08M	$149.84M	$146.83M	$163.67M	$146.07M	$122.48M	$130.64M	$126.04M	$107.9M	$97.33M
Selling & Marketing	-1.2%	+2.1%	+2.4%	—	$457.99M	$450.93M	$459.91M	$474.22M	$456.39M	$413.68M	$391.91M	$392.28M	$375.56M	$376.32M	$359.6M	$376.14M	$371.52M	$343.55M	$307.33M	$267.48M	$244.81M	$227.41M
General & Administrative	-1.1%	+2.4%	—	—	$125.68M	$113.43M	$119.25M	$129.73M	$128.08M	$111.68M	$112.26M	$104.57M	$102.08M	—	—	—	—	—	—	—	—	—
Amortization of Intangibles	-9.1%	-7.4%	-6.1%	—	$70.34M	$84.87M	$93.8M	$93.7M	$104.4M	$103.2M	$122.6M	$118.6M	$133.8M	$137.9M	$132M	$132.9M	$126.9M	$133.1M	$110.4M	$94.9M	$78.4M	$69.4M
Depreciation & Amortization	-2.4%	-1.1%	+0.1%	—	$193.75M	$203.27M	$205.34M	$208.4M	$214.93M	$205.01M	$231.46M	$206.44M	$216.45M	$213.06M	$191.47M	$200.78M	$199.36M	$197.89M	$167.38M	$142.78M	$48.58M	$42.62M
Restructuring Charges	—	—	—	—	—	—	—	—	—	—	—	—	—	$79.1M	—	—	—	$41M	$74.9M	—	—	—
Total Operating Expenses	-0.8%	-0.3%	+2.6%	—	$833.64M	$869.64M	$823.75M	$853.1M	$820.74M	$846.28M	$1.03B	$734.38M	$769.14M	$745.83M	$647.16M	$703.51M	$752.16M	$654.21M	$650.22M	$527.03M	$486.87M	$454.03M
Operating Income	-4.3%	+3.8%	+10.0%	—	$465.85M	$97.71M	$409.94M	$531.46M	$630.08M	$386.43M	-$26.14M	$266.58M	$153.42M	$98.83M	$179.5M	$161.69M	$63.33M	$169.81M	$99.59M	$188.54M	$180.21M	$145.66M
Operating Margin	—	—	—	—	22.29%	4.94%	20.86%	24.82%	27.98%	20.66%	-1.71%	17.75%	10.82%	7.39%	14.01%	12.02%	4.86%	13.54%	8.51%	17.34%	17.85%	16.31%
EBITDA	-3.8%	+2.2%	+5.9%	—	$659.6M	$300.98M	$615.27M	$739.86M	$845.02M	$591.45M	$205.32M	$473.02M	$369.87M	$311.88M	$370.97M	$362.48M	$262.69M	$367.71M	$266.97M	$331.32M	$228.78M	$188.28M
Interest Expense	-17.1%	-14.2%	-1.2%	—	$33.26M	$43.84M	$53.41M	$58.36M	$54.48M	$71.32M	$74.19M	$67.29M	$49.69M	$39.02M	$37.4M	$39.33M	$30.88M	$23.45M	$25.36M	$27.82M	$29.64M	$37.53M
Interest Income	+25.2%	+45.0%	+29.8%	—	$64.32M	$68.02M	$78.99M	$32.76M	$9.56M	$10.03M	$22.11M	$20.85M	$10.65M	$6.78M	$4.75M	$3.96M	$2.3M	$2.38M	$6.13M	$4.46M	$3.52M	$9.51M
Other Non-Operating Income	—	-14.4%	—	—	$24.41M	$23.44M	$19.87M	-$18.86M	-$4.25M	$53.04M	-$51.64M	-$40.84M	-$39.04M	-$41.92M	-$43.2M	-$42.3M	-$25.99M	-$24.66M	-$3.38M	-$15.42M	-$7.88M	-$26.38M
Equity in Earnings of Unconsolidated Entities	+5.4%	-2.6%	+20.9%	—	$4.4M	$5.72M	$4.16M	$3.76M	$11.99M	$5.02M	$2.08M	$2.59M	$3.16M	$2.82M	$661K	$3.48M	$1.75M	$1.85M	—	—	—	—
Investment Income (Loss)	—	—	—	—	-$968K	-$426K	$0	-$6.23M	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Pretax Income	-1.5%	+2.2%	+13.7%	—	$490.27M	$121.15M	$429.81M	$512.6M	$625.83M	$439.47M	-$77.78M	$225.74M	$114.38M	$56.91M	$136.3M	$119.39M	$37.34M	$145.15M	$96.21M	$173.12M	$172.33M	—
Income Tax	-9.9%	-4.0%	+26.2%	—	$65.39M	$37.56M	$88.51M	$89.39M	$113.23M	$80.28M	-$36.32M	$35.36M	$73.98M	-$23.4M	$6.4M	$2.46M	-$31.76M	$15.62M	$1.26M	$28.81M	$34.56M	$29.76M
Net Income	+0.1%	+3.4%	+12.6%	—	$424.88M	$83.59M	$341.3M	$423.21M	$512.6M	$359.19M	-$41.46M	$190.38M	$40.39M	$80.4M	$130.15M	$116.37M	$69.07M	$129.51M	$96.04M	$144.31M	$137.77M	$89.03M
Net Margin	—	—	—	—	20.33%	4.23%	17.37%	19.76%	22.77%	19.2%	-2.72%	12.68%	2.85%	6.01%	10.16%	8.65%	5.31%	10.32%	8.21%	13.27%	13.64%	9.97%
Net Income Attributable to Noncontrolling Interests	—	—	—	—	—	—	—	—	—	—	—	$0	$0	-$101K	-$246K	$568K	$25K	$31K	-$1.09M	$0	$0	$491K
Comprehensive Income	+14.7%	+4.2%	+57.0%	—	$522.11M	$42.88M	$311.56M	$345.79M	$429.75M	$424.99M	-$40.43M	$99.55M	$153.47M	$5.72M	$5.73M	-$14.18M	$20.89M	$157.59M	$47.19M	$158.92M	$172.76M	$29.16M
EPS (Basic) USD/shares	+1.8%	+4.5%	+13.3%	—	$1.96	$0.38	$1.50	$1.86	$2.25	$1.57	-$0.18	$0.84	$0.18	$0.34	$0.56	$0.50	$0.30	$0.55	$0.41	$0.62	$0.67	$0.45
EPS (Diluted) USD/shares	+1.8%	+4.9%	+13.4%	$2.43*	$1.94^G	$0.37	$1.48	$1.84	$2.21^G	$1.53	-$0.18	$0.82	$0.17	$0.34	$0.55	$0.48	$0.29	$0.54	$0.40	$0.60	$0.64	$0.44
Shares Outstanding (Basic Avg) shares	-1.5%	-1.0%	-0.7%	—	217.22M	222.62M	228.15M	227.58M	227.98M	228.43M	226.78M	226.64M	228.07M	234.8M	233.48M	232.64M	234M	235.58M	233.85M	232.64M	206.93M	196.8M
Shares Outstanding (Diluted Avg) shares	-1.7%	-1.3%	-0.9%	—	218.88M	224.72M	230.62M	230.14M	232.03M	234.21M	226.78M	233.46M	233.01M	238.99M	238.65M	242.81M	242.18M	240.75M	239.06M	240.48M	213.61M	204.26M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2010–FY2025: $1.25B in buybacks, $54.24M in dividends.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balance	As of	Amount	Source
Long-term debt, including current maturities	2025-12-31	USD 1,654,428,000	20-F filed 2026-03-20
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current portion of long-term debt USD 0 Line of credit borrowings, including current maturities USD 0 Noncurrent debt carrying amount USD 1,654,428,000
Operating lease liabilities	2025-12-31	USD 157,944,000	20-F filed 2026-03-20
Related accounting measures — not additional borrowing Carrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year. Current operating lease liabilities USD 28,837,000 Noncurrent operating lease liabilities USD 129,107,000

Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Peer median 6.70×

EV/EBIT

—

Peer median 36.58×

P/E (TTM)

—

Peer median 35.92×

Price/Sales (TTM)

—

Peer median 6.62×

Price/Book

2.78×

Peer median 6.22×

Peer medians compare against the 26 similar-size Diagnostics & Research companies (of 51 listed).

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	$2,089,999,000	$1,978,214,000	$1,965,311,000	$2,141,518,000

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$998,448,000	$942,009,000	$935,281,000	$909,616,000	$909,690,000	$728,577,000	$663,869,000	$632,660,000
EMEA	$712,759,000	$648,494,000	$624,573,000	$733,469,000	$814,417,000	$682,289,000	$487,476,000	$490,301,000
Asia Pacific and Rest of World	$290,727,000	$298,154,000	$320,683,000	$410,294,000	$429,864,000	$362,600,000	$316,958,000	$318,528,000
Other Americas	$88,065,000	$89,557,000	$84,774,000	$88,139,000	$97,686,000	$96,880,000	$58,121,000	$60,359,000
Netherlands	$23,700,000	$20,900,000	$20,300,000	$31,500,000	$28,300,000	$17,800,000	$15,800,000	$15,900,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Diagnostic Solutions	$803,080,000	$748,888,000	$697,630,000	$660,879,000	$638,759,000	$460,757,000	$465,503,000	$461,064,000
Sample Technologies	$661,265,000	$642,031,000	$662,991,000	$796,932,000	$850,636,000	$803,867,000	$548,365,000	$546,636,000
PCR Nucleic Acid Amplification	$308,992,000	$300,468,000	$300,204,000	$390,804,000	$433,972,000	$363,552,000	$224,685,000	$236,952,000
Genomics NGS	$241,775,000	$233,608,000	$238,910,000	$224,797,000	$245,066,000	$165,570,000	$183,768,000	$163,383,000
Product And Service Other	$74,887,000	$53,219,000	$65,576,000	$68,106,000	$83,224,000	$76,600,000	$104,103,000	$93,813,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	$465,851,000	$97,711,000	$409,938,000	$531,460,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022
Reportable Segment	22.3%	4.9%	20.9%	24.8%

Key facts CIK 1015820 CUSIP N72482156 13F (30d) 132 filings 113 filers Visit website Investor relations